2,674
Views
17
CrossRef citations to date
0
Altmetric
Original article

Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers

, , , , , , & show all
Pages 586-595 | Accepted 17 Mar 2015, Published online: 22 Apr 2015

References

  • Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA 2005;293:217-28
  • Margolis D, Malay DS, Hoffstad OJ, et al. Incidence of diabetic foot ulcer and lower extremity amputation among Medicare beneficiaries, 2006 to 2008. Data Points #2. AHRQ Publication No. 10(11)-EHC009-1-EF [article online]. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); 2011. http://www.effectivehealthcare.ahrq.gov/ehc/products/287/627/Data-points_2_Diabetic-Foot-Ulcer_Report_02-2011.pdf. Accessed November 4, 2014
  • Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999;22:382-7
  • Cook JJ, Simonson DC. Epidemiology and health care cost of diabetic foot problems. In: Veves A, Giurini JM, LoGerfo FW, eds. The diabetic foot. New York City: Springer, pp. 17-32. http://link.springer.com/book/10.1007%2F978-1-61779-791-0. Accessed February 24, 2015
  • Frykberg RG, Zgonis T, Armstrong DG, et al; American College at Foot and Ankle Surgeons. Diabetic foot disorders: a clinical practice guideline. J Foot Ankle Surg 2006;45:52-66
  • Lavery LA, Armstrong DG, Wunderlich RP, et al. Risk factors for foot infections in individuals with diabetes. Diabetes Care 2006;29:1288-93
  • Rice JB, Desai U, Cummings AK, et al. Burden of diabetic foot ulcers for Medicare and private insurers. Diabetes Care 2014;37:651-8
  • Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 1990;13:513-21
  • Armstrong DG, Wrobel J, Robbins JM. Guest Editorial: are diabetes-related wounds and amputations worse than cancer? Int Wound J 2007;4:286-7
  • Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment: a meta-analysis. Diabetes Care 1999;22:692-5
  • Apligraf prescribing information [online]. Organogenesis, Canton, MA. 2010. http://www.apligraf.com/professional/pdf/prescribing_information.pdf. Accessed November 4, 2014
  • Dermagraft prescribing information [online]. Organogenesis, Canton, MA. 2014. http://www.dermagraft.com/wp-content/uploads/sites/1/Dermagraft_Directions_For_Use1.pdf. Accessed November 4, 2014
  • Veves A, Falanga V, Armstrong DG, et al. Apligraf Diabetic Foot Ulcer Study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001;24:290-5
  • Marston WA, Hanft J, Norwood P, et al; Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003;26:1701-5
  • Kirsner RS, Sabolinski ML, Parsons NB, et al. A retrospective, comparative effectiveness analysis of bioengineered living cellular technologies and an acellular porcine collagen wound dressing for the treatment of diabetic foot ulcers in a real world setting. Poster presentation #CR 016, Symposium on Advanced Wound Care, October 17, 2014. Las Vegas, NV
  • Frykberg RG, Marston WA, Cardinal M. The incidence of lower-extremity amputation and bone resection in diabetic foot ulcer patients treated with a human fibroblast-derived dermal substitute. Adv Skin Wound Care 2015;28:17-20
  • Redekop WK, McDonnell J, Verboom P, et al. The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics 2003;21:1171-83
  • Zhang Y, Hogan P. Cost effectiveness of a human fibroblast-derived dermal substitute for the treatment of diabetic foot ulcers in Medicare and commercially insured populations. Diabetes 2011;60(1A Suppl):LB15-16
  • Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424
  • Margolis DJ, Bartus C, Hoffstad O, et al. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers. Wound Repair Regen 2005;13:531-6
  • Margolis DJ, Gupta J, Hoffstad O, et al. Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation: a cohort study. Diabetes Care 2013;36:1961-6
  • Margolis DJ, Kantor J, Santanna J, et al. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2001;24:483-8
  • Rice JB, Desai U, Cummings AK, et al. Burden of venous leg ulcers in the United States. J Med Econ 2014;17:347-56
  • Centers for Medicare and Medicaid Services. MLN Matters Article MM8572 [online]. Baltimore, MD. 2013. http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/MM8572.pdf. Accessed November 4, 2014
  • U.S. Bureau of Labor Statistics. Consumer Price Index [online]. Washington, DC. 2013. http://www.bls.gov/cpi/home.htm. Accessed November 4, 2014

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.